Wprowadzenie sakubitrylu + walsartanu w leczeniu niewydolności serca. Którzy pacjenci mogą odnieść największe korzyści z tego nowego leku? Artykuł przeglądowy


Rahil S. Hussain
Manpreet S. Kumar
Kelly Saka-Patrick
Ali J. Rezaee


Heart failure (HF) is a significant cause of morbidity and mortality in developed countries. Chronic activation of RAAS has been implicated in remodeling of the heart and progression of HF. In the past pharmacological therapies have been aimed at suppression of RAAS with β-blockers, ACE inhibitors, and mineralocorticoid receptor blockers being the cornerstone of HF therapy. Over the recent decades as the protective role of natriuretic peptides (ANP and BNP) became more clear in HF, efforts have been made in manipulating these vasoactive peptides to counter remodeling of the heart in HF patients. Initial strategies involved use of recombinant natriuretic peptides, however trials failed to show therapeutic benefits in HF patients. The next strategy was inhibition of neprilysin, an enzyme that degrades natriuretic peptides, with the goal of increasing endogenous levels of ANP and BNP. Over the years multiple trials failed to demonstrate superiority of various combination of drugs targeting neprilysin inhibition over the standard therapy (ACE inhibitor or ARB). A breakthrough was finally made when PARADIGM-HF trial showed that combination therapy with angiotensin receptor-neprilysin inhibitor (ARN-I) significantly lowered cardiovascular mortality and hospitalization as well as all-cause mortality in HFrEF (heart failure with reduced ejection fraction) patients compared to treatment with a proven dose of ACE inhibitor (enalapril 10 mg). Although ARN-I is FDA (US Food and Drug Administration) approved, currently its use remains limited in many countries because of lack of clinical experience and its potential life-threatening adverse effects (e.g. angioedema). It is recommended as a second-line agent in place of ACE inhibitor in HErEF patients who remain symptomatic despite optimal treatment with HF drugs. Despite the valuable lessons learned from PARADIGM-HF trial many questions are still left unanswered in regard to efficacy and safety of ARN-I in other subset of patients with HF who may benefit from its use.


Jak cytować
Hussain , R. S., Kumar , M. S., Saka-Patrick , K., & Rezaee , A. J. (2017). Wprowadzenie sakubitrylu + walsartanu w leczeniu niewydolności serca. Którzy pacjenci mogą odnieść największe korzyści z tego nowego leku?. Kardiologia W Praktyce, 11(1), 30-39. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1264


1. Ollendorf D.A., Sandhu A.T., Pearson S.D.: Sacubitril-Valsartan for the Treatment of Heart Failure. JAMA Intern. Med. 2016; 176(2): 249-250.
2. Rywik T.M., Kołodziej P., Targoński R. et al.: Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol. Pol. 2011; 69(1): 24-31.
3. McCormack P.L.: Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction. Drugs 2016; 76(3): 387-396.
4. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 2012; 33(14): 1787-1847.
5. Jhund P.S., McMurray J.J.V.: The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart 2016; 102(17): 1342-1347.
6. Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators: A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. N. Engl. J. Med. 2001; 345(23): 1667-1675.
7. Cohn J.N., Ferrari R., Sharpe N.: Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 2000; 35(3): 569-582.
8. Andersen S., Andersen A., Nielsen-Kudsk J.E.: The Renin–Angiotensin–Aldosterone-System And Right Heart Failure In Congenital Heart Disease. IJC Heart & Vasculature 2016; 11: 59-65.
9. Yan W., Sheng N., Seto M. et al.: Corin, a Mosaic Transmembrane Serine Protease Encoded by a Novel cDNA from Human Heart. J. Biol. Chem. 1999; 274(21): 14926-14935.
10. O’Connor C.M., Starling R.C., Hernandez A.F.: Effect Of Nesiritide In Patients With Acute Decompensated Heart Failure. N. Engl. J. Med. 2011; 365: 32-43.
11. Konishi M., Ishida J., Springer J. et al.: Heart Failure Epidemiology And Novel Treatments In Japan: Facts And Numbers. ESC Heart Failure 2016; 3(3): 145-151.
12. Bevan E.G., Connell J.M., Doyle J. et al.: Candoxatril, A Neutral Endopeptidase Inhibitor. J. Hypertens. 1992; 10(7): 607-614.
13. Packer M., Califf R.M., Konstam M.A. et al.: Comparison Of Omapatrilat And Enalapril In Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial Of Utility In Reducing Events (OVERTURE). Circulation 2002; 106(8): 920-926.
14. Ruilope L.M., Dukat A., Böhm M. et al.: Blood-Pressure Reduction With LCZ696, A Novel Dual-Acting Inhibitor Of The Angiotensin II Receptor And Neprilysin: A Randomised, Double-Blind, Placebo-Controlled, Active Comparator Study. Lancet 2010; 375(9722): 1255-1266.
15. Gu J., Noe A., Chandra P. et al.: Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARN-I). J. Clin. Pharmacol. 2010; 50(4): 401-414.
16. Hegde L.G., Yu C., Renner T. et al.: Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat. J. Cardiovasc. Pharmacol. 2011; 57(4): 495-504.
17. Bavishi C., Messerli F.H., Kadosh B. et al.: Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur. Heart J. 2015; 36(30): 1967-1973. http://doi.org/10.1093/eurheartj/ehv142.
18. Novartis: Entresto (sacubitril and valsartan): US pescribing information. 2015. Online.
19. Cada D.J., Baker D.E., Leonard J.: Sacubitril/Valsartan. Hosp. Pharm. 2015; 50(11): 1025-1036.
20. Chaplin S.: Sacubitril/Valsartan For The Treatment Of Heart Failure. Prescriber 2016; 27(4): 56-57.
21. Ejection Fraction Heart Failure Measurement. Online: http://www.heart.org/HEARTORG/Conditions/HeartFailure/DiagnosingHeartFailure/Ejection-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp#.WSrqDOvyiUk.

22. Fala L.: Entresto (Sacubitril/Valsartan): First-In-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved For Patients With Heart Failure. Am. Health Drug Benefits 2015; 8(6): 330-334.
23. Latini R., Masson S., Anand I. et al.: Effects Of Valsartan On Circulating Brain Natriuretic Peptide And Norepinephrine In Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-Heft). Circulation 2002; 106(19): 2454-2458.
24. Lee D.S., Gona P., Vasan R.S. et al.: Relation Of Disease Pathogenesis And Risk Factors To Heart Failure With Preserved Or Reduced Ejection Fraction: Insights From The Framingham Heart Study Of The National Heart, Lung, And Blood Institute. Circulation 2009; 119(24): 3070-3077.
25. Makani H., Messerli F.H., Romero J. et al.: Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am. J. Cardiol. 2012; 110(3): 383-391. http://doi.org/10.1016/j.amjcard.2012.03.034.
26. McMurray J.J., Packer M., Desai A.S. et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014; 371(11): 993-1004. http://doi.org/10.1056/NEJMoa1409077.
27. National institute for health and care excellence (NICE). Sacubitril Valsartan For Treating Symptomatic Chronic Heart Failure With Reduced Ejection Fraction. London: National institute for health and care excellence (NICE). Online: https://www.nice.org.uk/guidance/ta388.
28. Pellicori P., Urbinati A., Shah P. et al.: What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur. J. Heart Fail. 2017; 19(6): 768-778. http://doi.org/10.1002/ejhf.788.
29. Potter L.R., Abbey-Hosch S., Dickey D.M.: Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 2006; 27(1): 47-72.
30. Ramzy I.: Standards And New Drugs In The Treatment Of Heart Failure. E-journal of Cardiology Practice 2017; 14(39): 1-5.
31. Solomon S.D., Zile M., Pieske B. et al.: The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851): 1387-1395.
32. Vardeny O., Miller R., Solomon S.D.: Combined Neprilysin And Renin-Angiotensin System Inhibition For The Treatment Of Heart Failure. JACC Heart Fail. 2014; 2(6): 663-670. http://doi.org/10.1016/j.jchf.2014.09.001.
33. Bayes-Genis A., Morant-Talamante N., Lupón J.: Neprilysin and natriuretic peptide regulation in heart failure. Curr. Heart Fail. Rep. 2016; 13(4): 151-157.
34. Chaplin S.: Sacubitril/valsartan for chronic heart failure: its future potential. Prescriber 2016; 27(11): 26-34.
35. Ponikowski P., Voors A.A., Anker S.D.: 2016 ESC Guidelines For The Diagnosis And Treatment Of Acute And Chronic Heart Failure – Web Addenda. Eur. Heart J. 2016. http://doi.org/10.1093/eurheartj/ehw128.
36. Feldman A.M., Haller J.A., DeKosky S.T.: Valsartan/Sacubitril for Heart Failure. JAMA 2016; 315(1): 25-26.
37. Iwata N., Tsubuki S., Takaki Y. et al.: Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 2000; 6(2): 143-150.
38. Jhund P.S., Claggett B., Packer M. et al.: Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur. J. Heart Fail. 2014; 16(6): 671-677. http://doi.org/10.1002/ejhf.76.
39. Paulus W.J., Tschöpe C.: A novel paradigm for heart failure with preserved ejection fraction. JACC 2013; 62(4): 263-271.
40. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines For The Diagnosis And Treatment Of Acute And Chronic Heart Failure: The Task Force For The Diagnosis And Treatment Of Acute And Chronic Heart Failure Of The European Society Of Cardiology (ESC) Developed With The Special Contribution Of The Heart Failure Association (HFA) Of The ESC. Eur. Heart J. 2016; 37(27): 2129-2200.
41. Sacubitril/Valsartan For Chronic Heart Failure. Aust. Prescr. 2016; 39(6): 226-227.
42. Williams B., Cockcroft J.R., Kario K. et al.: Effects Of Sacubitril/Valsartan Versus Olmesartan On Central Hemodynamics In The Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension 2017; 69(3): 411-420. http://doi.org/10.1161/HYPERTENSIONAHA.116.08556.
43. Williams B., Cockcroft J.R., Kario K. et al.: Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open 2014; 4(2): e004254. http://doi.org/10.1136/bmjopen-2013-004254.
44. Pellicori P., Clark A.L.: Clinical Evidence To Support The Use Of Sacubitril/Valsartan (LCZ696). Br. J. Cardiol. 2016; 23(supl. 1): S1-S16.
45. Pellicori P., Clark A.L.: Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure. Eur. J. Heart Fail. 2015; 17(9): 979-983. http://doi.org/10.1002/ejhf.340.
46. Madani R., Poirier R., Wolfer D.P. et al.: Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J. Neurosci. Res. 2006; 84(8): 1871-1878.
47. Iwata N., Tsubuki S., Takaki Y. et al.: Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 2000; 6(2): 143-150.
48. EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE). Online: https://clinicaltrials.gov/ct2/show/NCT02816736. Identification number: NCT02816736.
49. Prospective ARN-I vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) (2016). Online: https://clinicaltrials.gov/ct2/show/NCT02924727. Identification number: NCT02924727.
50. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON- HF) (2013). Online: https://clinicaltrials.gov/ct2/show/NCT01920711. Identification number: NCT01920711.